Pages that link to "Q33590458"
Jump to navigation
Jump to search
The following pages link to (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor (Q33590458):
Displaying 50 items.
- Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs (Q26766039) (← links)
- Targeted therapy in advanced bladder cancer: what have we learned? (Q27009469) (← links)
- Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer (Q27011840) (← links)
- Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas (Q28076210) (← links)
- Pazopanib in the treatment of soft tissue sarcoma (Q28269229) (← links)
- Pazopanib, a new therapy for metastatic soft tissue sarcoma (Q28287163) (← links)
- Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer (Q33430940) (← links)
- Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer. (Q33431429) (← links)
- Programmed death-ligand 1 expression is associated with fibrosarcomatous transformation of dermatofibrosarcoma protuberans (Q33684256) (← links)
- Successful use of pazopanib for treatment of refractory metastatic hemangiopericytoma (Q34264348) (← links)
- Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study (Q34340390) (← links)
- Pazopanib, a Receptor Tyrosine Kinase Inhibitor, Suppresses Tumor Growth through Angiogenesis in Dedifferentiated Liposarcoma Xenograft Models (Q35028802) (← links)
- Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study (Q35074974) (← links)
- Utility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application (Q35233993) (← links)
- Concise drug review: pazopanib and axitinib (Q36182836) (← links)
- Preoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS). (Q36472317) (← links)
- Angiogenesis-related pathways in the pathogenesis of ovarian cancer (Q37139109) (← links)
- Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours (Q37182210) (← links)
- Pazopanib, a novel multi-kinase inhibitor, shows potent antitumor activity in colon cancer through PUMA-mediated apoptosis (Q37709464) (← links)
- Pharmacokinetic evaluation of axitinib (Q37976135) (← links)
- Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. (Q38028124) (← links)
- New drugs in sarcomas. (Q38165238) (← links)
- Pazopanib for the treatment of renal cell carcinoma (Q38400468) (← links)
- Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor (Q38498207) (← links)
- Pazopanib in ovarian cancer (Q38571120) (← links)
- Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review (Q38936104) (← links)
- The Role of PDGFs and PDGFRs in Colorectal Cancer. (Q39120772) (← links)
- Pharmacokinetic drug evaluation of pazopanib for the treatment of uterine leiomyosarcomas (Q39415429) (← links)
- Pazopanib: a promising new agent in the treatment of soft tissue sarcomas (Q39683594) (← links)
- Dried blood spot analysis for therapeutic drug monitoring of pazopanib (Q40881271) (← links)
- Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules (Q41658065) (← links)
- Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). (Q41679292) (← links)
- Determination of pazopanib (GW-786034) in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry (LC/MS-MS). (Q42236729) (← links)
- Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization (Q47131757) (← links)
- Pazopanib for renal cell carcinoma leads to elevated mean arterial pressures in a murine model. (Q47367575) (← links)
- Immunotherapeutic Targeting of Tumor-Associated Blood Vessels (Q49592831) (← links)
- An exploratory study investigating the metabolic activity and local cytokine profile in patients with melanoma treated with pazopanib and paclitaxel. (Q51746622) (← links)
- Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas. (Q52671439) (← links)
- The Impact of Pazopanib on the Cardiovascular System. (Q52715902) (← links)
- Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin). (Q53167144) (← links)
- The multi-kinase inhibitor pazopanib targets hepatic stellate cell activation and apoptosis alleviating progression of liver fibrosis. (Q53381128) (← links)
- Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy (Q60925489) (← links)
- FGFR1 expression defines clinically distinct subtypes in pancreatic cancer (Q60928286) (← links)
- Relative Dose Intensity of Induction-Phase Pazopanib Treatment of Soft Tissue Sarcoma: Its Relationship with Prognoses of Pazopanib Responders (Q61802368) (← links)
- Systematic Review of the Current Status of Human Sarcoma Cell Lines (Q64245211) (← links)
- Targeting Tumor Microenvironment for Cancer Therapy (Q64259998) (← links)
- Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site (Q86706636) (← links)
- Identification of Angiogenesis Inhibitors Using a Co-culture Cell Model in a High-Content and High-Throughput Screening Platform (Q89014503) (← links)
- Pazopanib Monotherapy Is Active in Relapsed and Refractory Metastatic Gastroesophageal Adenocarcinoma and Can Produce Durable Response (Q89370037) (← links)
- Phase-II Trials of Pazopanib in Metastatic Neuroendocrine Neoplasia (mNEN): A Systematic Review and Meta-Analysis (Q92134477) (← links)